EASL 2023

LEARN ABOUT A CRITICAL DIFFERENTIAL DIAGNOSIS FOR ABDOMINAL PAIN

Acute hepatic porphyria (AHP) is a genetic disorder of heme biosynthesis that is characterized by potentially life-threatening attacks, chronic symptoms, and long-term complications[1-3]

Although attacks can present with broad symptomatology, AHP should be suspected in patients who exhibit a combination of symptoms, referred to as the "classic triad"[4-8]



25% to 35% of patients with AHP also present with hyponatraemia and 37% to 55% present with dark urine

Patients with AHP often experience high disease burden and diminished quality of life, regardless of attack frequency[1,9]

AHP is frequently overlooked due to the non-specific nature of the presenting symptoms.[7] AHP should be considered in patients with severe, recurrent abdominal pain of unknown aetiology[10]

An early, accurate diagnosis and regular clinical assessments can improve the patient experience of living with AHP[2,11]

Visit the Alnylam booth at F1 next to the Biotech Village to find out more about AHP

Alnylam will be presenting two posters at EASL 2023; please see the abstract book for details

For further information on AHP, visit thinkporphyria.eu. If you would like to sign up to receive further information about AHP from Alnylam, please go to alnylamconnect.eu

We look forward to seeing you at the Alnylam booth!

For healthcare professionals only
The booth and posters will contain information on products developed and marketed by Alnylam Pharmaceuticals
Developed and funded by Alnylam Pharmaceuticals

References: 1. Gouya L, Ventura P, Balwani M, et al. *Hepatology*. 2020;71(5):1546-1558; **2.** Balwani M, Wang B, Anderson KE, et al; for the Porphyrias Consortium of the Rare Diseases Clinical Research Network. *Hepatology*. 2017;66(4):1314-1322; **3.** Simon A, Pompilus F, Querbes W, et al. *Patient*. 2018;11(5):527-537; **4.** Anderson KE, Bloomer JR, Bonkovsky HL, et al. *Ann Intern Med*. 2005;142(6):439-450; **5.** Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, et al. *J Inherit Metab Dis*. 2018;41(5):809-817; **6.** Simon NG, Herkes GK. *J Clin Neurosci*. 2011;18(9):1147-1153; **7.** Ventura P, Cappellini MD, Biolcati G, et al. *Eur J Intern Med*. 2014;25(6):497-505; **8.** Anderson KE, Desnick RJ, Stewart MF, et al. *Am J Med Sci*. 2022;363(1):1-10; **9.** Buendía-Martínez J, Barreda-Sánchez M, Rodríguez-Peña L, et al. *Orphanet J Rare Dis*. 2021;16(1):106; **10.** Wang B, Bonkovsky HL, Lim JK, Balwani M. *Gastroenterology*. 2023;164(3):484-491; **11.** Neeleman RA, Wensink D, Wagenmakers MAEM, et al. *Neth J Med*. 2020;78(4):149-160

Alnylam Netherlands B.V.
Antonio Vivaldistraat 150
1083 HP Amsterdam
Netherlands

Alnylam® PHARMACEUTICALS

AS1-CEMEA-00446

04.2023